Product description Hydrophilic Dual-Linker Building Block for Long-Acting GLP Peptide Side Chains (Core Function)
The long-acting modification strategy used in semaglutide and tirzepatide relies on a long-chain fatty acid + γ-Glu + dual AEEA structure to achieve an optimal balance between hydrophobicity and hydrophilicity. The long-chain fatty acid enhances albumin binding to prolong plasma half-life, while the dual AEEA polyether linker significantly improves peptide water solubility and prevents aggregation or precipitation caused by lipid modification. This product contains a preassembled dual-AEEA unit that can be introduced into the side chain through a single coupling step, replacing two sequential single-AEEA coupling reactions. It effectively reduces side-chain truncation impurities, shortens the synthetic process, and serves as an essential hydrophilic building block for the industrial-scale production of long-acting GLP peptide side chains.
Protection-Group Free – No TFA Deprotection Required
This molecule contains no acid-labile protecting groups such as tert-butyl esters, Fmoc, or sulfonyl groups. It remains stable during coupling reactions, and only the OtBu group on the fatty acid/γ-glutamic acid fragment of the complete side chain requires deprotection. The use of this intermediate introduces no additional deprotection steps, simplifying downstream processing and purification.
No Intrinsic Pharmacological Activity – Synthetic Intermediate Only
This compound is a small polyether amide molecule without any structural motifs responsible for GLP receptor binding, glucose-lowering activity, or cosmetic functions. It has no therapeutic efficacy when administered alone by injection, oral administration, or topical application. Its sole purpose is to serve as an intermediate for constructing lipid-modified peptide side chains.
Universal Hydrophilic Linker for Lipid-Modified Peptides
In addition to semaglutide and tirzepatide, this building block is suitable for the synthesis of side chains for all long-acting GLP peptides modified with C18/C20 fatty acids, as well as hydrophilic linkers for antibody-drug conjugates (ADCs). The dual-AEEA structure is a widely adopted industry-standard hydrophilic spacer that improves water solubility and minimizes aggregation associated with long hydrophobic lipid chains.
For Research and Industrial Manufacturing Only
This product is an upstream organic synthesis intermediate for active pharmaceutical ingredient (API) manufacturing. It is intended exclusively for use in peptide side-chain synthesis during industrial production and must not be used for direct injection, oral administration, or topical application.